{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Mesoblast completes dosing in 350-patient back-pain Phase 3 trial","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://assets.newatlas.com/dims4/default/28eb8b0/2147483647/strip/true/crop/2000x1050+0+88/resize/1200x630!/quality/90/?url=https%3A%2F%2Fnewatlas-brightspot.s3.ap-southeast-2.amazonaws.com%2F8e%2F03%2F3b3ba4ab461d96c987a379d20c04%2Fdepositphotos-349126404-l.jpg&na.image_optimisation=0","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/CQ00XUAshg_7s3LqdY5xbm\" style=\"color:#fff;text-decoration:none;\">Mesoblast completes dosing in 350-patient back-pain Phase 3 trial</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Mesoblast has completed the patient-treatment stage of its Phase 3 trial of rexlemestrocel-L for chronic low back pain, according to New Atlas. The trial enrolled 350 people, expanded from 300, with h...</p>\n    </blockquote>"}